Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds

Information

  • Patent Grant
  • 9186297
  • Patent Number
    9,186,297
  • Date Filed
    Friday, May 3, 2013
    11 years ago
  • Date Issued
    Tuesday, November 17, 2015
    8 years ago
Abstract
The invention relates generally to materials for facilitating the administration of dimethyl sulfoxide (DMSO) and related compounds. In one embodiment, the invention comprises a kit comprising items used for the safe and effective administration of DMSO. In another embodiment, the invention relates to indicating containers for holding or delivering DMSO.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The invention relates generally to materials for facilitating the administration of dimethyl sulfoxide (DMSO) and related compounds. In one embodiment, the invention comprises a kit comprising some or all of the items desired for the safe and effective administration of DMSO to medical patients in a hospital, ambulance, EMT or other environment. In another embodiment, the invention relates to polymeric materials used to construct devices, such as indicating containers, that facilitate DMSO administration.


2. Description of the Related Art


With the greatly increased use and anticipated use of DMSO in medical treatments for serious injuries and illness, technology that facilitates the administration of DMSO is becoming increasingly important. Although DMSO has several uses as a medicament, many clinicians are reluctant to administer DMSO to their patients because of the difficulty in administering DMSO. Not only does the metabolism of DMSO produce noxious odors, but DMSO is a member of the subset of chemical compounds known as “super solvents” because few polymers are insoluble in DMSO. Because most compounds dissolve in DMSO, containers for holding or delivering DMSO in a manner that does not cause leaching of (or chemical reactions with) DMSO are not readily available.


The IV tubing most commonly used today in hospitals is plasticized PVC (polyvinyl chloride) wherein both the PVC and the plasticizers are readily dissolved by DMSO. Substitutes for PVC and its plasticizers that have been incorporated in the recent art also are a cancer and other serious health risk and will dissolve in DMSO. Examples of DMSO soluble chemicals include PVC and its plasticizers DEHP and TOTM, acrylics, styrenes, polyamides, urethanes and silicones. The danger of DMSO in use with common polymers poses serious risk. Not only will common polymers be degraded by DMSO such that perforations will cause ineffective containment of DMSO, but the degradation or reaction with DMSO of certain polymers can result in toxic by-products.


Polyolefins such as polybutylene, polypropylene, polyethylene, and their copolymers are insoluble in DMSO, but tubing formed from these materials is known to kink and crack too easily for use in IV systems. Similarly, bags made of these materials are difficult to form and may not withstand severe handling. An additional complication is the known fact that few polymers bond to polyolefins.


Likewise, although medical kits and IV kits are routinely used in ambulatory and hospital settings, Applicant believes that no such kits are available that address the specific safety and handling requirements of DMSO. As DMSO becomes a much more routine drug of choice for the treatment of seriously ill or injured patients, the success of these treatment methods will require immediate access to all of the particular items necessitated by the presence of DMSO and related compounds. Patient treatment items must be immediately available in sterile condition. These items are simply not currently available in ordinary hospital, ambulance, EMT or medical practice.


SUMMARY OF THE INVENTION

Preferred embodiments of the invention relate to materials to facilitate the administration of DMSO and associated compounds.


Several embodiments of the present invention relate to a material designed to withstand exposure to DMSO and associated compounds. In one embodiment, the invention comprise a container for holding or transporting DMSO and/or associated compounds. The term “container” as used herein shall be given its ordinary meaning and shall include carriers, holders, enclosures, and conduits for containing, holding, administering, delivering, or transporting materials such as DMSO and associated compounds.


The phrases “DMSO associated compounds”, “associated compounds”, or related compounds as used herein shall be given their ordinary meaning and shall include degradation compounds, derivatives, precursors, and metabolites of DMSO, such as methylsulfonylmethane (MSM or DMSO2) and dimethyl sulfide or methylthiomethane (DMS).


The phrase “DMSO container” as used herein shall be given its ordinary meaning and shall include containers that are adapted to contain DMSO and associated compounds.


The tem “kit” as used herein shall be given its ordinary meaning and shall also mean a system, grouping, and collection of materials provided for a common goal.


In one embodiment, the invention comprises a device for facilitating administration of DMSO. The device comprises a container for holding or delivering DMSO wherein the container comprises an inner layer, an outer layer, and an intermediate layer. The inner layer comprises a material that is insoluble in DMSO. The inner layer may also be impervious to fluids. The intermediate layer comprises a material that contacts the inner layer and outer layer. The outer layer is resistant to abrasion. The container may be an IV bag, tubing, a syringe, or a catheter.


In one embodiment of the invention, the DMSO container comprises a single or multilayer material for safely and effectively containing DMSO. In one embodiment, the material is polymeric.


In one embodiment, the inner layer of the container comprises a material that will not dissolve in DMSO or related compounds. Thus, in some embodiments, the inner layer will be able to endure exposure to DMSO (for minutes, hours, days, months, or longer) without changing the chemical or physical nature of the container. In one embodiment, the inner layer of the container is insoluble, inert, and/or non-reactive with DMSO. The inner layer may comprise a homophase copolymer of propylene.


In one embodiment, the outer layer comprises a thermoplastic polymer, and is resistant to abrasion.


In one embodiment, the intermediate layer comprises a binding layer for binding the inner layer and said outer layer. The intermediate layer may comprises a polyamide film that bonds said inner layer and said outer layer. The intermediate layer may comprise a 9 through 13-aminoundecanoic acid polyamide. The intermediate layer may comprise a polyolefin.


In another embodiment, the invention comprises a DMSO container and an indicator to indicate that DMSO has leached through one or more layers of the container. The indicator may be on the inside or outside of the container. The indicator may be integral with the container, coupled to the container, or a separate component. The indicator may be located on or within the inner layer. The indicator may be located on the outside of the inner layer, or in between the inner layer and the intermediate layer. The indicator may be located in between the intermediate layer and the outer layer.


In one embodiment, the indicator comprises a visual indicator or colorant that changes color if DMSO leaches out of the inner layer. The colorant may warn of commingling of the layers during manufacturing, a manufacturing failure that could result in the intermediate layer being exposed to DMSO and leaching into the IV solution. In one embodiment, at least one portion of the container is transparent so as to visually indicate a color change. The indicator may comprise a compound, such as a chemical compound, that reacts or changes color upon exposure to DMSO, and is thereby adapted to signal escape of DMSO from the inner layer (or another layer) of said container. The indicator may comprises a compound that changes light transmission upon exposure to DMSO, and is thereby adapted to signal escape of DMSO from the inner layer of said container.


In a further embodiment, the invention comprises making a container according to any one of the embodiments described herein. In one embodiment, the material for the container is made by co-extrusion.


Several embodiments of the present invention relate to a medical supply kit assembled for the purpose of making the necessary items available to medical personnel administering DMSO and related compounds to medical patients in hospital, ambulance, or EMT conditions. In one embodiment, the invention comprises all of the specific items required for the administration of DMSO. Several embodiments of the invention comprise kits to make the administration of DMSO and its associated compounds as efficient, effective and safe as possible.


In one embodiment, the invention comprises a kit comprising one or more of the containers according to any one of the embodiments described herein. In one embodiment, the kit further comprises one or more of the following: instructions for use; a DMSO resistant stainless steel IV needle; a DMSO resistant IV catheter; a syringe; and DMSO. The kit may also contain other components, as described below.


In one embodiment, the kit comprises a detector for detecting the presence of DMSO or related compound. The kit may also include adsorbant material for adsorbing the noxious odors associated with DMSO metabolism. The adsorbant material, includes, but is not limited to, caps, gowns, scrubs, and linens.


In another embodiment, the kit comprises at least one adsorbent depletion indicating cartridge for a respiratory ventilator exhaust to capture the metabolites of DMSO passing from the respiration of the patient.


In yet another embodiment, the kit comprises at least one pair of protective caregiver gloves constructed of a suitable hypoallergenic rubberized material including modified or unmodified structures of singular polyolefins and/or combinations of polyolefins or the extruded multilayer film as for the IV bag or IV tubing.


In one embodiment, the invention comprises a method for facilitating the administration of dimethyl sulfoxide (DMSO) or related compounds to a recipient. In one embodiment, the method comprises providing a device or container according to any one of the embodiments described herein. The method may also include providing dimethyl sulfoxide (DMSO) or a related compound. Additionally, a kit or kit components may be provided, along with instructions for use.







DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Embodiments of the present invention will be described as it applies to certain preferred embodiments. It is not intended that the present invention be limited to the described embodiment. It is intended that the invention cover all modifications and alternatives which may be included within the spirit and scope of the invention.


Preferred embodiments of the present invention comprise materials and devices to facilitate handling or administration of DMSO and associated compounds, and methods of making and using same.


In one embodiment, the invention comprises IV bags, tubing, and other carriers, containers, and conduits for DMSO and associated compounds.


In another embodiment, the invention comprises kits for the delivery and administration of DMSO and associated compounds.


Carriers, Containers, and Conduits for DMSO and Associated Compounds


In one embodiment, the invention comprises a container (including carriers and conduits such as IV bags and tubing) for holding or transporting DMSO and/or associated compounds. In one embodiment, the DMSO container comprises a plurality of layers.


In one embodiment, the DMSO container comprises three layers: at least one inner, fluid resistant, layer; at least one binding layer; and at least one outer, protective, layer.


In one embodiment, the first layer comprises a DMSO resistant homophase copolymer of propylene, wherein the polypropylene is a known material and is appreciated in many fields. In one embodiment, the first layer is capable of withstanding concentrations of DMSO of a trace to as much as 100% at temperatures up to the melting point in the range of about 110 to 160 degrees C. In one embodiment, heterophase polymers that are DMSO resistant may be used.


In one embodiment, the first layer comprises a homophase copolymer of propylene that contains from about 1% to 50% by weight of polyethylene and can be employed to particular advantage in the bonding of the layers.


In one embodiment, the intermediate binding layer may comprises suitable polyolefin binders. In another embodiment, the intermediate layer comprises at least one binding polymer. The binding polymer includes, but is not limited to, 13-aminoundecanoic acid, 12-aminoundecanoic acid, 11-aminoundecanoic acid, 10-aminoundecanoic acid, and 9-aminoundecanoic acid polyamide films. In one embodiment, the intermediate binding layer may comprise a transparent visual indicator or other indicator, or a combination of two or more indicators. The indicator that may be coupled to the intermediate layer may be in addition to, in instead of, the indicator that is coupled to the inner layer.


In one embodiment, the outer, protective, layer of the container (such as tubing and bags) comprises a polymer. In one embodiment, the outer layer comprises a tough, abuse-resistant thermoplastic polymers including, but not limited to, polyvinylidene chloride (PVDC) or ethylene vinyl alcohol (EVOH), or other polyamides. In one embodiment, the outer layer is resistant to abrasion. Sealants may be used instead of or in addition to the outer layer. An indicator may be part of, coupled to, or integral with the outer layer.


In one embodiment, the container comprises one or more indicators. The indicator will indicate or signal the escape of DMSO or associated compounds from the inner layer. In one embodiment, a visually indicating transparent colorant is included as an integral part of the homophase copolymer of the inner layer. Such transparent visual indicator (or other type of indicator) warns of commingling of the inner and intermediate layers during manufacture subjecting the DMSO soluble intermediate layer to the possibility of leaching into the IV solution. This becomes a significant quality control point for the products manufactured utilizing this method. This transparent color indicator also provides immediate identification by the caregiver of materials suitable for use with DMSO. An example of potential indictors would be a gold fleck completely immune to interaction with DMSO and associated compounds. Other indicators may be used as well. One advantage of an indicator according to some embodiments is that the indicator will promptly signal when DMSO or an associated compound has escaped from a safe layer (a layer that will not dissolve in DMSO) to a layer that is reactive or soluble with DMSO.


In one embodiment, the indicator comprises a light transmission changing indicator, such as a coating. In one embodiment, a plurality of microparticles may be dispersed between the layers of the container. A reagent formulated to change color and/or light transmission in response to the presence of moisture and/or DMSO in said matrix may be provided to indicate that DMSO and/or an associated compound has escaped the inner layer.


Some indicators may be sensitive to the chemical structure of DMSO and/or associated compounds. Some indicators may be sensitive to moisture content, while other indicators may signal the presence of gaseous molecules or fumes.


In one embodiment, indicators which change from translucent to clear are provided. Such indicators include, but are not limited to, metal chlorides, metal fluorides, metal hydroxides, metal carbonates, and metal nitrates. In one embodiment, alkali metal chlorides, alkaline earth metal chlorides or transition metal chlorides are used as indicators. These may be selected from the group alkali metal ozonide, lithium chloride, sodium hydroxide, potassium fluoride, potassium carbonate, potassium nitrate, magnesium chloride, stannous chloride, strontium chloride, aluminum chloride, calcium chloride, zinc chloride, calcium nitrate, sodium nitrate, ammonium chloride and ammonium nitrate. In some embodiments, these indicators will turn clear upon contact with moisture. In some embodiments, the presence of DMSO will increase the rate or intensity at which the indicators turn clear.


In one embodiment, a color changing indicating layer is provided. The indicator layer. The indicator layer of the container (which may be an additional layer or integral with the inner, intermediate, or outer layer) may comprise DMSO-absorptive or hygroscopic plastic such as cellulose acetate, cellulose acetate butyrate or a nylon, such as Nylon 408, and optionally, a fluid such as water. A cobalt salt is applied to, coupled with, or integral with the surface of the layer to provide a portion of the container characterized by a specific color in the absence of moisture and color change in the presence of moisture. Examples of cobalt salts which can be used include cobaltous chloride and cobaltous bromide. Various hygroscopic modifiers may also be added to enhance the moisture-grabbing properties of the hygroscopic plastic. Two of these hygroscopic modifiers include zinc chloride and calcium chloride. The quantity of hygroscopic modifiers hygroscopic may be varied to effect the moisture range to which the indicator is sensitive. In one embodiment, the change in color of a cobalt salt when moisture is introduced will be distinctive. For example, the color of cobaltous chloride is normally bluish when in a dry state but the color rapidly changes to a pinkish hue as moisture is absorbed by the hygroscopic plastic base. Likewise, the dry color of cobaltous bromide is greenish and the color changes to a yellowish hue as moisture is introduced. To obtain a desired initial or dry color, the aforementioned salts may be mixed.


In one embodiment, the indicator comprises a light transmission changing layer. The indicator layer of the container (which may be an additional layer or integral with the inner, intermediate, or outer layer) may comprise a DMSO-absorptive plastic such as cellulose acetate, cellulose acetate butyrate or a nylon, such as Nylon 408, and optionally, a fluid such as water. Particularly with the presence of DMSO, these materials would quickly turn from clear to cloudy or from transparent to translucent. Thus, in one embodiment, a cloudy or translucent appearance could be visually observed by a user. Alternatively, a light may be passed through the layer to detect cloudiness or translucency.


In one embodiment, a tubing expressly used to convey an IV solution bearing from a trace to as much as 100% DMSO, but preferentially in the range of 5 to 30% DMSO and/or associated compounds, is provided.


In another embodiment, a weldable bag to be used to store and dispense an IV solution bearing from a trace to as much as 100% DMSO, but preferentially in the range of 5 to 30% DMSO and/or associated compounds is provided.


In yet another embodiment, an easily inspectable device clearly indicating its suitability for use in DMSO bearing IV solutions is provided.


In a further embodiment, delivery of DMSO or DMSO related compounds for the prevention or treatment of illnesses is provided. In a preferred embodiment of the device, treatment of severe head injury, spinal chord injury, stroke or other neuropreventative/neurotherapeutic treatments is provided.


The inner layer, intermediate layer, and outer layer may have a individual or total thickness of about 0.0001 microns to about 10 cm. In one embodiment, each layer is about 0.0003 microns to about 4 cm thick. In one embodiment, the inner layer is about 1 mm to about 1 cm thick, the intermediate layer is about 1 mm to about 1 cm thick, and the outer layer is about 0.1 mm to about 1 cm thick. The thickness of each layer will depend on whether the container is an IV bag, tubing, a catheter, or a syringe. In some embodiments, the container comprises only one layer. In other embodiments, the container comprises more than three layers. In one embodiment, a layer may simply be a coating or dusting of particles.


In some embodiments, the containers will comprises features that are suited for the particular use of that container. Such features may be determined based on testing criteria. Testing criteria may be selected from a variety of testing methods. These may be similar to that described in U.S. Pat. No. 5,998,019, herein incorporated by reference. For example, a container may have specific properties that relate to autoclavability, low temperature ductility, mechanical modulus and recovery, RF processibility, optical clarity, strain whitening, environmental compatibility, and solution compatibility.


In several embodiments, the material selected for the construction of the container is based on the ability of the material to seal or close.


In other embodiments, the material selected for the construction of the container is based on compatibility with DMSO and other fluids, as for example, described in U.S. Pat. No. 5,998,019, herein incorporated by reference.


Kits for the Delivery and Administration of DMSO and Associated Compounds


In several embodiments, the present invention comprises a kit that facilitates the administration of DMSO and associated compounds. In one embodiment, the kit comprises several parts which are selected to be inclusive of all items needed for the procedure and to provide the features, resistance, and/or absorbency required by the special nature of DMSO and associated compounds.


In one embodiment, the kit comprises at least one container that comprises one of the layers described herein. The container included in the kit may be an IV bag, tubing, catheter, syringe, etc.


The list of materials for the DMSO IV kits may include, but is not limited to, the following components and may be divided as shown or in other ways as needed by the medical teams:


1. Patient Treatment Kit (Sterile Items):


In one embodiment, a surgical treatment kit or therapeutic treatment kit for treating patients with DMSO or DMSO compounds is provided. In one embodiment, the kit is specifically resistant to DMSO or DMSO compound and comprises one or more (and preferably, two or more) of the following:


a. Instructions for the procedure which may printed in fonts sized to be seen from across the room on large format E sized drawing paper. Each step is illustrated as well as described in detail. The instructions may be printed on the packaging material.


b. A full set of DMSO resistant Stainless Steel IV needles sized 16, 18, 19, 20, 21, 22 and 23 gauges. Said needles may be encased in moisture resistant packaging and accompanied by a corrosion inhibiting desiccant pad. A partial set or single needle can be included instead of the full set.


c. A full set of DMSO resistant IV Catheters sized to match the needles: 16, 18, 19, 20, 21, 22 and 23 gauges. A partial set or single catheter can be included instead of the full set.


d. Syringes in 10 ml, 20 ml and/or 50 ml sizes for the use of the medical professional should additional medicants be required in the IV.


e. The IV solution including DMSO in concentrations of about 1 volume percent through about 40 volume percent where the preferred concentration is about 28 volume percent. Additional compounds associated with DMSO IVs may be included. Concentrations less than 1% and higher than 40% may be provided in certain embodiments.


f. IV Bag or other container for the purpose of containing the above solution. Such bag may be marked with multiple linear scales including milliliters, DMSO dosage, and patient body weight. Included affixed to subject bag is a septum suitable for receiving additional medicament applied through use of the above syringes. The materials of construction for the subject bag comprise a multilayer film with the solution contacting liner completely resistant to DMSO and related compounds, an intermediate bonding layer and an outer abrasion resistant layer.


g. One or more containers that is manufactured by co-extrusion as a multilayer film with the solution contacting liner completely resistant to DMSO and related compounds, an intermediate bonding layer and an outer abrasion resistant layer.


h. Multiple tubing lengths and connectors and Y connectors to be used for special applications.


i. ‘Hoffmann’ style tubing clamps sized and uniquely structurally designed to match the durometer and diameter DMSO resistant tubing in the other parts of the kit.


j. Tape with a base paper or fabric and an adhesive selected to be resistant to the metabolites of DMSO and in particular to DMS (dimethyl sulfide) and to avoid all allergic combinations with DMS and associated compounds. Such tape to be used for affixing the tubing and catheter assembly to the patient and for applying a bandage to the needle puncture area.


k. Betadyne or equivalent sponges and alcohol wipes or other hypoallergenic non-DMSO or DMS or DMSO metabolite reacting preparatory fluid for the injection area of the patient.


l. A single use hypoallergenic elastic tourniquet suitable for short term exposure to DMS and the other metabolites of DMSO.


2. Patient Care Kit (Non-sterile Items)


A kit for providing odor control, chemical monitoring and safety equipment for use in treating patients with DMSO or related compounds (such as DMS) is provided. In a preferred embodiment, the kit comprises one or more of the following:


a. A suitable number of DMSO or related compounds (e.g., DMS) sensitive and indicating patches to pin or clip to the caregiver's clothing for the purpose of detecting and flagging for the caregiver the exposure level to DMS and related compounds.


b. A suitable number of DMSO or related compounds (e.g., DMS) adsorbent surgical style masks for the use of the caregivers to isolate them for the noxious odors of DMS and of the other metabolites of DMSO and associated compounds.


c. The kit may or may not also include protective caregiver caps, gowns, scrubs, and other specially treated adsorbent items to adsorb the noxious patient body odors of DMS and of the other metabolites of DMSO.


d. A DMSO or related compounds (e.g., DMS) and odor adsorbent Patient Quilt to adsorb the noxious patient body odors of DMS and of the other metabolites of DMSO and associated compounds.


e. A DMSO or related compounds (e.g., DMS) or odor adsorbent Patient Gown to adsorb the noxious patient body odors of DMS and of the other metabolites of DMSO and associated compounds.


f. An adsorbent depletion indicating cartridge for a respiratory ventilator exhaust to capture the metabolites of DMSO passing from the respiration of the patient.


g. Protective caregiver gloves constructed of a suitable hypoallergenic rubberized material including modified or unmodified structures of singular polyolefins and/or combinations of polyolefins or the extruded multilayer film as for the IV bag or IV tubing.


h. A suitable number of pairs of safety eyeglasses for the protection of the caregivers from exposure to the IV solution and bodily fluids associated with the procedure.


i. Hypoallergenic pure cotton balls and swabs for use for absorbing IV and bodily fluids associated with the procedure.


j. Additional protective and safety items as needed.


3. Sterile Venous Cut Down Kit


A venous cut down kit may or may not also be included for the purpose of immediately treating a patient where needle entry to the veins is prevented for any reason. Such a sub-kit may include one or more of following:


a. Scalpel


b. Hemostats


c. Forceps


d. Scissors


e. Sutures


A Portable Enclosure for the kits is also provided. In one embodiment, the enclosure may be a segmented hard or soft sided case organized in such a way that each item is arranged in the order of use and is readily accessible for selection by the caregiver. Such case is preferentially capable of being opened for display of all items. Individual kit items are clearly marked and identified so as to eliminate as much as possible any question related to the procedure. In one embodiment, the enclosure may comprise a molded or otherwise formed segmented or non-segmented base covered by an easily removable Tyvek® (E. I. Du Pont De Nemours And Company Corporation) or equivalent sheet.


EXAMPLES

The following examples describe non-limiting uses of the materials described herein.


A kit for treating a patient with severe closed head trauma is provided. The time between injury and treatment is extremely short where any success is desired in relieving patient symptoms. In a preferred embodiment, the medical staff would open the kit, fully exposing the contents; display the instructions for all to view and internalize, and proceed stepwise to complete the prescribed medical procedure.


A kit for treating a patient who may have suffered a stroke is provided. While often stroke may be difficult to diagnose, as soon as the diagnoses is clear, the caregivers must proceed immediately with the procedure. In a preferred embodiment, the medical staff would open the kit, fully exposing the contents; display the instructions for all to view and internalize, and proceed stepwise to complete the prescribed medical procedure.


Kits for the neuropreventative or neurotherapeutic treatment of patients diagnosed with, but not limited to, any of the following conditions are provided:


1. Head trauma


2. Stroke


3. Spinal cord


4. Organ Infarction


5. Dimentia


6. Alzheimers


7. CABG


8. Coronary Artery Disease


Kits for treatment using DMSO or DMSO related compounds to be applied at or in (but not limited to) one or more of the following environments are provided:


1. Ambulance


2. Hospital


3. Clinic


4. Medical office


5. Home


6. School


7. Sports stadium


8. Work place


9. Police station


Kits for treatment using DMSO to be applied in connection with (but not limited to) the following:


1. Neuroprotective


2. Neurotherapeutic


In a preferred embodiment, three kits would be provided for treatment of a patient with DMSO or DMSO related compounds. The first sterile kit, would be housed in a molded or injection formed plastic tray with a Tyvek® (E. I. Du Pont De Nemours And Company Corporation) lid, printed with instructions. The kit would include a 16 and 18 gauge angiocathers with Hoffmann clamps, an IV solution including DMSO in concentrations of 28 volume percent, betadyne or alcohol wipes and elastic tourniquet. The second kit would include non-sterile patient care items of items listed as 2 a, b, d, f, and g. The third kit would be a Venous cut down kit.


It will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the present invention. Therefore, it should be clearly understood that the forms of the present invention are illustrative only and are not intended to limit the scope of the present invention.

Claims
  • 1. An intravenous (IV) bag for holding or delivering dimethyl sulfoxide (DMSO), comprising: an inner layer, wherein the inner layer is fluid resistant and wherein in the inner layer is a material that is insoluble in DMSO;an outer protective layer;an intermediate binding layer comprising a binding material that contacts said inner and said outer layer; andan indicator layer positioned between the inner layer and the intermediate layer, wherein said indicator layer is configured to indicate that dimethyl sulfoxide (DMSO) and/or a related compound has escaped from the inner layer.
  • 2. The IV bag of claim 1, wherein the IV bag is configured to hold or deliver an IV solution having DMSO at levels from trace amounts to 100% DMSO.
  • 3. The IV bag of claim 2, wherein the IV bag is configured to hold or deliver an IV solution having DMSO at levels from 5% to 30% DMSO.
  • 4. The IV bag of claim 1, wherein the indicator layer comprises a light transmission changing indicator.
  • 5. The IV bag of claim 4, wherein the light transmission changing indicator comprises a DMSO-absorptive plastic.
  • 6. The IV bag of claim 5, wherein the DMSO-absorptive plastic turns from clear to cloudy or from transparent to translucent upon exposure to DMSO, thereby visually indicating that DMSO and/or a related compound has escaped from the inner layer.
  • 7. The IV bag of claim 1, wherein the indicator layer comprises a color changing indicator.
  • 8. The IV bag of claim 7, wherein the color changing indicator comprises a compound that changes color upon exposure to moisture related to the escape of DMSO and/or a related compound from the inner layer.
  • 9. The IV bag of claim 1, wherein the indicator layer comprises a coating or dusting of indicator particles between the inner and the intermediate layer.
  • 10. The IV bag of claim 1, wherein the intermediate layer comprises a polyamide film that binds the inner and the outer layer.
  • 11. The IV bag of claim 1, wherein the outer layer comprises a thermoplastic polymer.
  • 12. The IV bag of claim 1, wherein the IV bag is prepared by co-extrusion.
  • 13. A kit for facilitating the administration of dimethyl sulfoxide (DMSO) comprising: a) a container for holding or delivering dimethyl sulfoxide (DMSO) comprising: an inner layer, wherein the inner layer is fluid resistant and wherein the inner layer is a material that is insoluble in dimethyl sulfoxide (DMSO);a protective outer layer;an intermediate binding layer comprising a binding material that binds the inner and the outer layers; andan indicator layer disposed between the inner layer and the intermediate layer and configured to indicate whether DMSO and/or a related compound has escaped from the inner layer;b) at least one DMSO resistant catheter;c) at least one DMSO resistant needle; andd) instructions for use.
  • 14. The kit of claim 13, further comprising DMSO.
  • 15. The kit of claim 13, further comprising an adsorbant material for adsorbing odors associated with DMSO and/or related compounds.
  • 16. The kit of claim 13, wherein the kit is for treating a patient in need of neuroprotective and/or neurotherapeutic treatment.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/066,480, now U.S. Pat. No. 8,435,224, issued May 7, 2013, which is the U.S. National Phase under U.S.C. §371 of International Application No. PCT/US2006/035499, filed Sep. 11, 2006 (published as WO 2007/033180A1), which claims priority to U.S. Provisional Application Ser. Nos. 60/716,265 and 60/716,368, both of which were filed Sep. 12, 2005, and the entirety of each of which is herein incorporated by reference.

US Referenced Citations (508)
Number Name Date Kind
2638179 Yard May 1953 A
3334012 Herschler Aug 1967 A
3361555 Herschler Jan 1968 A
3393080 Erdi et al. Jul 1968 A
3419619 Soder et al. Dec 1968 A
3482572 Grosclaude et al. Dec 1969 A
3527863 Weichselbaum Sep 1970 A
3549770 Herschler et al. Dec 1970 A
3549771 Herschler Dec 1970 A
3551554 Herschler Dec 1970 A
3558434 Herschler Jan 1971 A
3573214 Kollonitsch Mar 1971 A
3592936 Marcus et al. Jul 1971 A
3654165 Bryant et al. Apr 1972 A
3675654 Baker et al. Jul 1972 A
3690808 St. Pierre Sep 1972 A
3711606 Herschler Jan 1973 A
3740420 Herschler et al. Jun 1973 A
3757495 Sievers Sep 1973 A
3773838 Andruski et al. Nov 1973 A
3790682 Herschler et al. Feb 1974 A
3823676 Cook et al. Jul 1974 A
3852408 Ewan et al. Dec 1974 A
3861894 Marsh Jan 1975 A
3881003 Rehm Apr 1975 A
3948617 Withorn Apr 1976 A
3972962 Williams et al. Aug 1976 A
3976747 Shale et al. Aug 1976 A
3988129 Fornoff et al. Oct 1976 A
3996295 Goeb Dec 1976 A
4015025 Szczesniak Mar 1977 A
4112946 Herschler Sep 1978 A
4125589 deVries Nov 1978 A
4129122 Dout et al. Dec 1978 A
4169550 Williams Oct 1979 A
4177267 Herschler Dec 1979 A
4194628 Campos Mar 1980 A
4202676 Pelosi, Jr. et al. May 1980 A
4212392 McKenzie Jul 1980 A
4225381 Ishikawa et al. Sep 1980 A
4252054 Bakels Feb 1981 A
4256728 Nishino et al. Mar 1981 A
4277450 Dilworth Jul 1981 A
4296104 Herschler Oct 1981 A
4296130 Herschler Oct 1981 A
4307067 Tagawa et al. Dec 1981 A
4309393 Nguyen Jan 1982 A
4316795 Mooi Feb 1982 A
4333922 Herschler Jun 1982 A
4335148 Vidal et al. Jun 1982 A
4341675 Nakamura Jul 1982 A
4350245 Elstner Sep 1982 A
4357288 Oas et al. Nov 1982 A
4369190 Schulte Jan 1983 A
4372915 Neti et al. Feb 1983 A
4413109 Haas Nov 1983 A
4424330 Raviola Jan 1984 A
4469702 Schulte Sep 1984 A
4477469 Herschler Oct 1984 A
4491563 Reusser et al. Jan 1985 A
4493930 Klayman et al. Jan 1985 A
4497824 Schulte Feb 1985 A
4505708 Gajewski et al. Mar 1985 A
4507114 Bohman et al. Mar 1985 A
4510292 Chiba et al. Apr 1985 A
4512245 Goldman Apr 1985 A
4514421 Herschler Apr 1985 A
4545414 Baum Oct 1985 A
4550010 Chelu Oct 1985 A
4559329 Herschler Dec 1985 A
4568547 Herschler Feb 1986 A
4575515 Sandborn Mar 1986 A
4591497 Naito et al. May 1986 A
4595102 Cianci et al. Jun 1986 A
4600002 Maryyanek et al. Jul 1986 A
4616039 Herschler Oct 1986 A
4616064 Zukosky et al. Oct 1986 A
4622221 Schleppnik Nov 1986 A
4626530 Schulte Dec 1986 A
4634588 Moroe Jan 1987 A
4642177 Mester et al. Feb 1987 A
4652557 Sandborn Mar 1987 A
4655148 Winship Apr 1987 A
4656094 Kojima et al. Apr 1987 A
4684380 Leichnitz Aug 1987 A
4686204 Mester et al. Aug 1987 A
4710353 Tanaka et al. Dec 1987 A
4719105 Schleppnik Jan 1988 A
4721813 Mark et al. Jan 1988 A
4725290 Ohlmeyer et al. Feb 1988 A
4728712 Singh et al. Mar 1988 A
4729835 McNeillie et al. Mar 1988 A
4737173 Kudirka et al. Apr 1988 A
4747845 Korol May 1988 A
4751241 Motoyama et al. Jun 1988 A
4778697 Genske et al. Oct 1988 A
4784909 Emi et al. Nov 1988 A
4796790 Hamilton Jan 1989 A
4797274 Miki et al. Jan 1989 A
4803047 Pluim, Jr. Feb 1989 A
4830718 Stauffer May 1989 A
4834721 Onohara et al. May 1989 A
4850268 Saito et al. Jul 1989 A
4863687 Stevens et al. Sep 1989 A
4863748 Herschler Sep 1989 A
4887751 Lehman Dec 1989 A
4902489 Watanabe Feb 1990 A
4902558 Henriksen Feb 1990 A
4904520 Dumas et al. Feb 1990 A
4910803 Cukier Mar 1990 A
4911691 Aniuk et al. Mar 1990 A
4914135 Herschler Apr 1990 A
4916767 Uetake et al. Apr 1990 A
4919925 Ueda et al. Apr 1990 A
4931276 Franco et al. Jun 1990 A
4933169 Shanbrom Jun 1990 A
4937115 Leatherman Jun 1990 A
4940405 Kelly Jul 1990 A
4940658 Allen et al. Jul 1990 A
4941991 Rajamannan Jul 1990 A
4946720 Oishi et al. Aug 1990 A
4948643 Mueller Aug 1990 A
4948787 Chen et al. Aug 1990 A
4956183 Miki et al. Sep 1990 A
4973605 Herschler Nov 1990 A
4978687 Pascuchi Dec 1990 A
4980045 Krishna et al. Dec 1990 A
4988505 Watanabe et al. Jan 1991 A
4990311 Hirai et al. Feb 1991 A
4994245 Murray et al. Feb 1991 A
5001794 Uetake et al. Mar 1991 A
5006510 Ellis Apr 1991 A
5007999 Chin Apr 1991 A
5032613 Watson Jul 1991 A
5041273 Rock Aug 1991 A
5049159 Yamaji et al. Sep 1991 A
5049163 Huang et al. Sep 1991 A
5055279 Hirt et al. Oct 1991 A
5059477 Henriksen Oct 1991 A
5070597 Holt et al. Dec 1991 A
5071622 Dunson, Jr. Dec 1991 A
5071686 Genske et al. Dec 1991 A
5071878 Herschler Dec 1991 A
5083558 Thomas et al. Jan 1992 A
5086804 Ngai Feb 1992 A
5087673 Watanabe et al. Feb 1992 A
5091180 Walker et al. Feb 1992 A
5117821 White Jun 1992 A
5133788 Backus Jul 1992 A
5135904 Kamiya et al. Aug 1992 A
5139831 Mueller Aug 1992 A
5143831 Wong et al. Sep 1992 A
5145657 Kobayashi et al. Sep 1992 A
5149576 Potts et al. Sep 1992 A
5152814 Nelson Oct 1992 A
5160707 Murray et al. Nov 1992 A
5169217 Orchard et al. Dec 1992 A
5182016 Funkenbusch et al. Jan 1993 A
5183656 Uesaka et al. Feb 1993 A
5190640 Roof et al. Mar 1993 A
5192272 Faure Mar 1993 A
5192342 Baron et al. Mar 1993 A
5192498 Chen et al. Mar 1993 A
5199263 Green et al. Apr 1993 A
5207303 Oswalt et al. May 1993 A
5213680 Kremer et al. May 1993 A
5218036 Kagawa et al. Jun 1993 A
5218147 Shaw Jun 1993 A
5240478 Messina Aug 1993 A
5260090 Isao Nov 1993 A
5269294 Rogozinski Dec 1993 A
5290331 Miles et al. Mar 1994 A
5335373 Dangman et al. Aug 1994 A
5336431 Richards et al. Aug 1994 A
5344529 Stauffer Sep 1994 A
5356709 Woo et al. Oct 1994 A
5358443 Mitchell et al. Oct 1994 A
5360468 Schubert Nov 1994 A
5409769 Fukumoto et al. Apr 1995 A
5415180 Horan May 1995 A
5419812 Beal May 1995 A
5439454 Lo et al. Aug 1995 A
5441729 Salce et al. Aug 1995 A
5458848 Burgaud Oct 1995 A
5458861 Buchanan et al. Oct 1995 A
5460625 Johnson Oct 1995 A
5466757 Watanabe et al. Nov 1995 A
5480860 Dillon Jan 1996 A
5486387 Mueller Jan 1996 A
5487766 Vannier Jan 1996 A
5494587 Morlec et al. Feb 1996 A
5512144 Stauffer Apr 1996 A
5516526 Da la Torre May 1996 A
5521268 Ghyzel et al. May 1996 A
5531987 Bauer et al. Jul 1996 A
5538545 Dauber et al. Jul 1996 A
5562127 Fanselow et al. Oct 1996 A
5569679 Jacob Oct 1996 A
5578540 Banzi et al. Nov 1996 A
5582865 Rezuke et al. Dec 1996 A
5584986 Bartholic Dec 1996 A
5603696 Williams et al. Feb 1997 A
5605635 David Feb 1997 A
5607647 Kinkead Mar 1997 A
5616408 Oleszczuk et al. Apr 1997 A
5620760 Galimberti et al. Apr 1997 A
5624649 Gal Apr 1997 A
5626820 Rezuke et al. May 1997 A
5650329 Warner Jul 1997 A
5654061 Visioli Aug 1997 A
5658801 Poissant et al. Aug 1997 A
5667799 Caldwell et al. Sep 1997 A
5703152 Ohama Dec 1997 A
5712044 Fanselow et al. Jan 1998 A
5725893 Pittet et al. Mar 1998 A
5753696 Shealy et al. May 1998 A
5761362 Yang et al. Jun 1998 A
5779679 Shaw Jul 1998 A
5783269 Heilmann et al. Jul 1998 A
5789046 Mueller Aug 1998 A
5792505 Fulger et al. Aug 1998 A
5803130 Robben et al. Sep 1998 A
5803249 Harsanyi, Jr. et al. Sep 1998 A
5843420 Bauer et al. Dec 1998 A
5849846 Chen et al. Dec 1998 A
5861096 Mason et al. Jan 1999 A
5871562 Culoso Feb 1999 A
5885566 Goldberg Mar 1999 A
5891508 Barnum Apr 1999 A
5919877 Tanaglia Jul 1999 A
5928744 Heilmann et al. Jul 1999 A
5931303 Salvadori Aug 1999 A
5935412 Brainard, II Aug 1999 A
5935547 LeComte et al. Aug 1999 A
5948398 Hanamoto et al. Sep 1999 A
5958502 Fulger et al. Sep 1999 A
5965276 Shlenker et al. Oct 1999 A
5967061 Ashworth et al. Oct 1999 A
5972993 Ptchelintsev Oct 1999 A
5989497 Labonte, Jr. Nov 1999 A
5998019 Rosenbaum et al. Dec 1999 A
6007520 Sudo Dec 1999 A
6010666 Kurokawa et al. Jan 2000 A
6012586 Misra Jan 2000 A
6015536 Lokkesmoe et al. Jan 2000 A
6030494 Hupa et al. Feb 2000 A
6042640 Isganitis et al. Mar 2000 A
6045596 Holland, Jr. et al. Apr 2000 A
6048733 Machino et al. Apr 2000 A
6057018 Schmidt May 2000 A
6060083 Dorr et al. May 2000 A
6060152 Murchie May 2000 A
D427299 Haslebacher Jun 2000 S
6070578 Baughman et al. Jun 2000 A
6071905 Krasnov et al. Jun 2000 A
6077335 Schneider et al. Jun 2000 A
6090076 Lane, Jr. Jul 2000 A
6094549 Hiraoka et al. Jul 2000 A
6099607 Haslebacher Aug 2000 A
6106502 Richmond Aug 2000 A
6106596 Haramoto et al. Aug 2000 A
6110176 Shapira Aug 2000 A
6114586 Devaux et al. Sep 2000 A
D431353 Mellin Oct 2000 S
D431902 Mellin Oct 2000 S
6183708 Hei et al. Feb 2001 B1
6183758 Scott Feb 2001 B1
6197288 Mankoo Mar 2001 B1
6207106 Kurokawa et al. Mar 2001 B1
6221325 Brown et al. Apr 2001 B1
6228960 Tanaglia May 2001 B1
6238767 McCormack et al. May 2001 B1
6248733 Landgrebe et al. Jun 2001 B1
6261655 Rosenbaum et al. Jul 2001 B1
6267941 Sata Jul 2001 B1
6277344 Hei et al. Aug 2001 B1
6294161 Hiramoto et al. Sep 2001 B1
6303200 Woo et al. Oct 2001 B1
6312713 Korol et al. Nov 2001 B1
6318075 Gunther et al. Nov 2001 B1
6348177 Bartley et al. Feb 2002 B1
6349826 Kapik et al. Feb 2002 B1
6365099 Castrantas et al. Apr 2002 B1
6403642 Berg Jun 2002 B1
6403739 Tanaglia et al. Jun 2002 B1
6406767 Mueller Jun 2002 B1
6412639 Hickey Jul 2002 B1
6414194 Bloom, Jr. et al. Jul 2002 B1
6416772 Van Engelen et al. Jul 2002 B1
6418932 Paschal, Jr. et al. Jul 2002 B2
6426112 Boatright Jul 2002 B1
6426370 Hofschneider Jul 2002 B1
6432891 O'Connor Aug 2002 B1
6440391 Jacob Aug 2002 B1
6454097 Blanco Sep 2002 B1
6458828 Sakurai et al. Oct 2002 B1
6460702 Hammond Oct 2002 B2
6461631 Dunn et al. Oct 2002 B1
6465068 Patel et al. Oct 2002 B1
6468259 Loretti et al. Oct 2002 B1
6475466 Ricci et al. Nov 2002 B1
6479150 Liu et al. Nov 2002 B1
6479488 Di-Fabio et al. Nov 2002 B1
6482377 Bartley et al. Nov 2002 B2
6495096 Hamaguchi et al. Dec 2002 B1
6528080 Dunn et al. Mar 2003 B2
6531111 Whalen, II et al. Mar 2003 B1
6552231 Jones et al. Apr 2003 B2
6562447 Wu et al. May 2003 B2
6579444 Feimer et al. Jun 2003 B2
6579543 McClung Jun 2003 B1
6599472 Hudson Jul 2003 B1
6620911 Pettit et al. Sep 2003 B1
6632842 Chaudry et al. Oct 2003 B2
6638605 Ankuda, Jr. et al. Oct 2003 B1
6639110 Fremy Oct 2003 B2
6649193 Colic Nov 2003 B1
6652845 Hu et al. Nov 2003 B2
6653352 Barr et al. Nov 2003 B2
6656723 Phillips Dec 2003 B1
6663679 Duncan Dec 2003 B1
6680194 Turner Jan 2004 B1
6706257 McCook et al. Mar 2004 B1
6718914 Riddles Apr 2004 B2
6722295 Zauderer Apr 2004 B2
6723349 Hill et al. Apr 2004 B1
6723399 Chundury et al. Apr 2004 B2
6734263 Eadara et al. May 2004 B2
6737031 Beal et al. May 2004 B2
6737089 Wadsworth et al. May 2004 B2
6743523 Woo et al. Jun 2004 B1
6743951 Fremy Jun 2004 B2
6761169 Eswarappa Jul 2004 B2
6761912 Forusz et al. Jul 2004 B2
6764566 Griesbach, III et al. Jul 2004 B1
6783004 Rinner Aug 2004 B1
RE38597 Lane, Jr. Sep 2004 E
6796958 Chen et al. Sep 2004 B2
6797042 LaFerriere et al. Sep 2004 B2
6822015 Muraki Nov 2004 B2
6830794 Cartledge et al. Dec 2004 B2
6844430 Pesce et al. Jan 2005 B2
6846535 De Groot et al. Jan 2005 B2
6858192 Graham et al. Feb 2005 B2
6872241 Soane et al. Mar 2005 B2
6881419 Lovett Apr 2005 B2
6884797 Hofmann Apr 2005 B2
6890373 Nemoto et al. May 2005 B2
6902714 Skaarup Jensen et al. Jun 2005 B2
6908885 Bengs et al. Jun 2005 B2
6927305 Choudary et al. Aug 2005 B2
7057016 Cerletti Jun 2006 B2
7203974 Jones et al. Apr 2007 B2
7282224 Roederer Oct 2007 B1
7371407 Farmer May 2008 B2
7381521 Whitaker Jun 2008 B2
7955418 Claussen et al. Jun 2011 B2
8298320 Cozean Oct 2012 B2
8435224 Claussen et al. May 2013 B2
8440001 Cozean May 2013 B2
8480797 Cozean et al. Jul 2013 B2
8673061 Cozean et al. Mar 2014 B2
20010005766 Fremy Jun 2001 A1
20010018095 Shlenker et al. Aug 2001 A1
20010047038 Moorman et al. Nov 2001 A1
20020015762 Quinlan Feb 2002 A1
20020025983 Horrobin Feb 2002 A1
20020032131 O'Connor Mar 2002 A1
20020043501 Irvine Apr 2002 A1
20020090398 Dunn et al. Jul 2002 A1
20020110549 Till Aug 2002 A1
20020115729 Yang Aug 2002 A1
20020131933 Delmotte Sep 2002 A1
20020133100 Paschal, Jr. et al. Sep 2002 A1
20020151753 Fremy Oct 2002 A1
20020156326 Fremy Oct 2002 A1
20020179647 Hall et al. Dec 2002 A1
20020182263 Stenti et al. Dec 2002 A1
20030017183 Pollock Jan 2003 A1
20030032616 Moskowitz et al. Feb 2003 A1
20030082321 Kennedy et al. May 2003 A1
20030085170 Scranton et al. May 2003 A1
20030108810 Williamson et al. Jun 2003 A1
20030109495 Kretschmer Jun 2003 A1
20030118672 McPeak et al. Jun 2003 A1
20030133959 Shacknai et al. Jul 2003 A1
20030149007 Chaudry et al. Aug 2003 A1
20030152862 Williamson et al. Aug 2003 A1
20030157006 Hei et al. Aug 2003 A1
20030167033 Chen et al. Sep 2003 A1
20030190266 Tsurumi Oct 2003 A1
20030203009 MacDonald Oct 2003 A1
20030203484 Black et al. Oct 2003 A1
20030226443 Rajagopalan et al. Dec 2003 A1
20040016410 Riddles Jan 2004 A1
20040039066 Crea Feb 2004 A1
20040048376 Chabot et al. Mar 2004 A1
20040057972 Shacknai et al. Mar 2004 A2
20040074212 Yachi et al. Apr 2004 A1
20040081673 Rayner et al. Apr 2004 A1
20040082667 McCadden et al. Apr 2004 A1
20040086888 Kornblith et al. May 2004 A1
20040087669 Hausmanns et al. May 2004 A1
20040105643 Bishop et al. Jun 2004 A1
20040115818 Puri et al. Jun 2004 A1
20040121023 Stevens Jun 2004 A1
20040131806 Barmore et al. Jul 2004 A1
20040137136 Zheng et al. Jul 2004 A1
20040151826 Milligan Aug 2004 A1
20040154220 Holcomb Aug 2004 A1
20040156742 Milan et al. Aug 2004 A1
20040157802 Horwitz et al. Aug 2004 A1
20040186316 Choudary et al. Sep 2004 A1
20040197339 Brown Oct 2004 A1
20040213755 Hochwalt et al. Oct 2004 A1
20040213774 Till Oct 2004 A9
20040219126 Seto et al. Nov 2004 A1
20040242818 Williamson et al. Dec 2004 A1
20040265291 Drake et al. Dec 2004 A1
20050025840 Revnolds Feb 2005 A1
20050031651 Gervais et al. Feb 2005 A1
20050031761 Brucker et al. Feb 2005 A1
20050035062 Hiltzik et al. Feb 2005 A1
20050054875 Hei et al. Mar 2005 A1
20050058630 Harris et al. Mar 2005 A1
20050069598 Ribnicky et al. Mar 2005 A1
20050084412 MacDonald et al. Apr 2005 A1
20050084438 Do et al. Apr 2005 A1
20050084464 McGrath et al. Apr 2005 A1
20050084474 Wu et al. Apr 2005 A1
20050092070 Bhatti May 2005 A1
20050092761 Marganski et al. May 2005 A1
20050095653 Goldstein et al. May 2005 A1
20050112085 MacDonald et al. May 2005 A1
20050112176 Dopson et al. May 2005 A1
20050112177 Dopson et al. May 2005 A1
20050115895 Simpson et al. Jun 2005 A1
20050136082 Soane et al. Jun 2005 A1
20050136125 Roth Jun 2005 A1
20050142096 Wegner Jun 2005 A1
20050147692 Roth Jul 2005 A1
20050158406 McPeak et al. Jul 2005 A1
20050158424 Nakano et al. Jul 2005 A1
20050169826 Li Aug 2005 A1
20050176778 Vermeer Aug 2005 A1
20050181048 Romero Aug 2005 A1
20050182076 Pacheco et al. Aug 2005 A1
20050187124 Li et al. Aug 2005 A1
20050191343 Liang Sep 2005 A1
20050215515 Bucolo et al. Sep 2005 A1
20050222275 Gabizon et al. Oct 2005 A1
20050224409 Harshman et al. Oct 2005 A1
20050226827 Ho Oct 2005 A1
20050227910 Yang et al. Oct 2005 A1
20050260306 Baldus Nov 2005 A1
20050261257 Vermeer Nov 2005 A1
20050265979 Aoki et al. Dec 2005 A1
20050266064 McCarthy Dec 2005 A1
20050281883 Daniloff et al. Dec 2005 A1
20060003069 Zheng et al. Jan 2006 A1
20060006120 Chen et al. Jan 2006 A1
20060006121 Simpson et al. Jan 2006 A1
20060018933 Vaya et al. Jan 2006 A1
20060018934 Vaya et al. Jan 2006 A1
20060024365 Vaya et al. Feb 2006 A1
20060052438 Ho et al. Mar 2006 A1
20060121613 Havens Jun 2006 A1
20060127508 Larkins Jun 2006 A1
20060143767 Yang et al. Jul 2006 A1
20060166948 Vermeer Jul 2006 A1
20060177398 McCook et al. Aug 2006 A1
20060194759 Eidelson Aug 2006 A1
20060210646 Oku et al. Sep 2006 A1
20060281822 Appleton Dec 2006 A1
20070025950 Elson Feb 2007 A1
20070028772 Jain et al. Feb 2007 A1
20070048386 Mallozzi, Sr. et al. Mar 2007 A1
20070180544 Taylor Aug 2007 A1
20070183936 Newsam et al. Aug 2007 A1
20070243146 Klock Oct 2007 A1
20070264212 Ho Nov 2007 A1
20070270358 Paoliambrosi Nov 2007 A1
20070292493 Brierre Dec 2007 A1
20080038219 Mosbaugh et al. Feb 2008 A1
20080076831 Goetz Mar 2008 A1
20080102107 Lewellyn et al. May 2008 A1
20080146458 Hollingsworth et al. Jun 2008 A1
20080193427 Kaesler et al. Aug 2008 A1
20080228161 Claussen et al. Sep 2008 A1
20080249082 Hollander Oct 2008 A1
20080251081 Claussen et al. Oct 2008 A1
20080260871 Fruitman Oct 2008 A1
20080274153 Farmer Nov 2008 A1
20080275015 Potter Nov 2008 A1
20080300311 Kisak et al. Dec 2008 A1
20080317680 Dueva-Koganov et al. Dec 2008 A1
20080319092 Singh et al. Dec 2008 A1
20090215888 Jagat et al. Aug 2009 A1
20090312273 De la Torre Dec 2009 A1
20090324784 McLellan et al. Dec 2009 A1
20110105623 Benjamin et al. May 2011 A1
20110136210 Benjamin et al. Jun 2011 A1
20110203583 Cozean Aug 2011 A1
20110203585 Cozean Aug 2011 A1
20120207827 Cozean et al. Aug 2012 A1
20130018059 Jacob et al. Jan 2013 A1
20130045941 Cozean et al. Feb 2013 A1
20140116444 Cozean et al. May 2014 A1
Foreign Referenced Citations (44)
Number Date Country
2 617 934 Feb 2007 CA
0 827 744 Mar 1998 EP
0 976 726 Feb 2000 EP
2 028 162 Dec 1979 GB
2003-306446 Oct 2003 JP
2005-0270589 Oct 2005 JP
2005 330199 Dec 2005 JP
2035909 May 1995 RU
WO 8500108 Jan 1985 WO
WO 9405272 Mar 1994 WO
WO 9405273 Mar 1994 WO
WO 9503753 Feb 1995 WO
WO 0064868 Nov 2000 WO
WO 0173096 Oct 2001 WO
WO 03015760 Feb 2003 WO
WO 03101415 Dec 2003 WO
WO 2004064877 Aug 2004 WO
WO 2004067013 Aug 2004 WO
WO 2004093541 Nov 2004 WO
WO 2004100896 Nov 2004 WO
WO 2005054553 Jun 2005 WO
WO 2005115546 Dec 2005 WO
WO 2005117913 Dec 2005 WO
WO 2006129149 Dec 2006 WO
WO 2006135854 Dec 2006 WO
WO 2007009245 Jan 2007 WO
WO 2007016766 Feb 2007 WO
WO 2007033082 Mar 2007 WO
WO 2007033083 Mar 2007 WO
WO 2007033180 Mar 2007 WO
WO 2007049262 May 2007 WO
WO 2007056205 May 2007 WO
WO 2007098591 Sep 2007 WO
WO 2007126191 Nov 2007 WO
WO 2008049020 Apr 2008 WO
WO 2008091704 Jul 2008 WO
WO 2008098871 Aug 2008 WO
WO 2010054093 May 2010 WO
WO 2010062721 Jun 2010 WO
WO 2011053848 May 2011 WO
WO 2011053854 May 2011 WO
WO 2011053874 May 2011 WO
WO 2011053875 May 2011 WO
WO 2011123695 Oct 2011 WO
Non-Patent Literature Citations (122)
Entry
Jacob, Web page entitled DMSO Dimethyl Sulfoxide, www.dmso.org; retrieved from the internet on Mar. 25, 2010.
Jacob, Web page entitled Dr. Jacob's Quality Assurance, www.Jacoblab.com; as published on the Internet on Sep. 8, 2004.
Jacob, Web page Dr. Jacob's Quality Assurance, Natural Healthcare Solutions; wwwjacoblab.com; retrieved from Internet on Mar. 25, 2010.
Adam, JB, Summary of Biomedical Treatments for Autism, ARI Publication 40, Apr. 2007.
Additive Free MSM Methylsulfonylmethane. World Image Naturals™, Inc. 2005. Downloaded from http://www.worldimagenaturals.com/products/msm/index.php. pp. 1-6.
Aleksevich lal, Piletskaia IG, Nikonorova VP. Increase in the sensitivity of the microflora of pathological gingival pockets to streptomycin under the influence of dimexide and trypsin. Mikrobiol Zh. Nov.-Dec. 1973; 35(6):766-9.
AloeCalm™ All-Natural and Organic Body Lotion. Lanique Botanicals™. Downloaded from http://www.acne-answers.org/products/aloe-calm.html on Jul. 5, 2010. pp. 1-5.
Andrews, Jennifer M.: “Determination of minimum inhibitory concentrations,” Journal of Antimicrobial Chemotherapy (2001) 48, Suppl. S1, 5-16.
Baer P, Thomas L, Shainhouse JZ. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomized, controlled 6-week trial. BMC Musculoskeletal Disord. 2005; 6:44.
Barrager, et al. A Multicentered, Open-Label Trial on the Safety and Efficacy of Methylsulfonylmethane in the Treatment of Seasonal Allergic Rhinitis, The Journal of Alternative and Complementary Medicine, vol. 8, No. 2, 2002, pp. 167-173.
Beilke, et al.: “Effects of dimethyl sulfoxide on the oxidative function of human neutrophils,” (1987) Journal of Laboratory and Clinical Medicine 110:91-96.
Berry et al. Natural Gas Odorants Desulfurization, (2004) AlChE Annual National Meeting, Austin, Texas, Nov. 7-12.
Blumenthal L, Fuchs M. The Clinical Use of Dimethyl Sulfoxide on Various Headaches, Musculoskeletal and Other General Medical Disorders. Annals New York Academy of Sciences 1967:572-585.
Bookman A, Williams S, Shainhouse J. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ Aug. 17, 2004; 171(4):333-338.
Borodina, et al.: “Dimethylsulfone as a growth substrate for novel methylotrophic species of Hyphomicrobium and Arthrobacter,” Arch Microbiol (2000) 173: 425-437.
Brandt, et al.: “Selective Affinity of Dimethyl Sulphoxide (DMSO) and 2-amino-4-phenylsulphonylbenzenesulphonamide (NSD 3004) for the Large Intestinal Mucosa of Mice,” Acta pharmacol. Et toxicol. 1982, 51, 173-176.
Brayton CF. Dimethyl Sulfoxide (DMSO); A Review. The Cornel Veterinarian. Jan. 1986; 76(1):61-90.
Brechner V, Cohen D, Pretsky I. Dermal Anesthesia by the Topical Application of Tetracaine Base Dissolved in Dimethyl Sulfoxide, Annals New York Academy of Sciences. 1967:524-531.
Brien et al. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis and Cartilage (2008) 16:1277-1288.
Brien S, Prescott P, Lewith G. Meta-analysis of the Related Nutritional Supplements Dimethyl Sulfoxide and Methylsulfonlymethane in the Treatment of Osteoarthritis of the Knee. eCAM Advance Access published May 27, 2009 in 10 pages.
Brown, Derek, F.J., et al.: “Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant staphylococcus aureus (MRSA),” Journal of Antimicrobial Chemotherapy (2005) 56, 1000-1018.
Brown JH. Clinical Experience with DMSO in Acute Musculoskeletal Conditions, Comparing a Noncontrolled Series with a Controlled Double Blind Study. Ann NY Acad Sci 1967; 141(1):496-505.
Cárdenas, et al., “Fructose-1,6-bisphosphate inhibits the expression of inducible nitric oxide synthase caused by oxygen-glucose deprivation through the inhibition of glutamate related in rat forebrain slices”, Arch. of Pharmacol., vol. 362(3):208-121 (2000).
Cherian L, Robertson C. L-Arginine and Free Radical Scavengers Increase Cerebral Blood Flow and Brain Tissue Nitric Oxide Concentrations after Controlled Cortical Impact Injury in Rats. Journal of Neurotrauma, vol. 20, No. 1, 2003; (Jan. 2003), pp. 77-85.
Dancer, S. J.: “The effect of antibiotics on methicillin-resistant Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy (2008) 61, 246-253.
Database WPI, Week 199604, Thomson Scientific.
de Lencastre, et al.: “Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power,” Curr Opin Microbial. Oct. 2007; 10(5): 428-435.
Debi R, et al. The Role of MSM in Knee Osteoarthritis: A Double Blind, RandomizedProspective Study. Osteoarthritis and Cartilage (2008) 15 Supplemental C:C231 (426).
Demos C et al. Dimethyl Sulfoxide in Musculoskeletal Disorders. Ann NY Acad Sci 1967:517-523.
Eberhardt et al. DMSO in patients with Active Gonarthrosis. A double-blind, placebo-controlled Phase III Study. Fortschr Med, Nov. 10, 1995: 113(31):446-450.
Evans MS, Reid KH, Sharp JB. Dimethylsulfoxide (DMSO) blocks conduction in peripheral nerve C fibers: a possible mechanism of analgesia. Neuroscience Letters, 150 (1993):145-148.
Feldman WE, Punch JD, Holden PC. In vivo and in vitro effects of dimethyl sulfoxide on streptomycin-sensitive and -resistant Escherichia coli. Ann NY Acad Sci, Jan. 27, 1975; 243:269-77.
Florain, The Solid State Structures of the Dimethylformamide and Dimethylsulfoxide Complexes of Dioxodichloromolybdenum (VI), ProQuest, 30-07B (1969), pp. 66.
Gerhards & Gibian, “The Metabolism of Dimethyl Sulfoxide and Its Metabolic Effect in Man and Animals,” Annals New York Academy of Sciences, pp. 65-76, Mar. 1967.
Glasser D. Dimethylsulfoxide (DMSO) “resensibilization” as potential chemotherapy for opportunistic mycobacterial disease. Am Rev Respir Dis. Nov. 1978; 118(5):969-70.
Gorbach IN, Samtsov VS. Therapeutic possibilities of inhalation of rifampicin with dimexide in phthisiopulmonology. Probl Tuberk. 1991; (3):34-6.
“Guidance on Medical Device Patient Labeling” accessed Mar. 10, 2010. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070782.htm.
Gupta, Shyam Dr.: “New Delivery System for Topical Nutraceutical (Nutracosmetic) and Cosmeceutical Formulations,” pp. 1-5, Business Briefing: Global Cosmetics Manufacturing 2004.
Haigler HJ et al. Comparison of the Analgesic Effects of Dimethyl Sulfoxide and Morphine, Ann NY Acad Sci 1983; (411):19-27.
Hasegawa T, Suppressive Effects of Methylsulfonylmethane (MSM) on Type II Collagen-induced Arthritis in DBA/1J Mice. Jpn Pharmacol Ther 2004; 32 (7):421-427.
Horváth, et al.: “Toxicity of methylsulfonylmethane in rats,” Food and Chemical Toxicology 40 (2002) 1459-1462.
How to Flush the Toxins out of Your Body from the Swine or H1N1 Flu Shot, downloaded from http://www.ehow.com/print/how—5625054—flush-swine-hn-flu-shot.html, on Aug. 18, 2010. pp. 1-3.
Hucker, et al.: “Studies on The Absorption, Excretion and Metabolism of Dimethylsulfoxide (DMSO) in Man,” The Journal of Pharmacology and Experimental Therapeutics, 155:309-317. 1967.
Jacob & Herschler: “Introductory Remarks: Dimethyl Sulfoxide After Twenty Years,” Annals New York Academy of Sciences, Jun. 1983.
Jacob S, Appleton J. MSM: The Definitive Guide—Chapter 6, 45-54, Part II, Chapter 7, 57-68, Chapter 8, 69-76, Chapter 10, 84-90, Chapter 21, 181-186. California: Freedom Press, 2003.
Jacob S, Lawrence R, Zucker M, The Miracle of MSM—The Natural Solution for Pain. New York: Library of Congress Cataloging-in-Publication Data, 1999.
Jacob SW, Herschler R. Pharmacology of DMSO, Cryobiology, 1985, 23(1):14-27.
Jacob, S.W. and Wood, D.C. Dimethyl sulfoxide (DMSO): Toxicology, pharmacology, and clinical experience. Am. J. Surg. 1967; 114(3):414-426.
Jacob et al., Interstitial Cystitis Network—Char Log, Topic: Understanding DMSO; Mar. 28, 2000; The IC Network.
Jagannath C, Reddy VM, Gangadharam PR. Enhancement of drug susceptibility of multi-drug resistant strains of Mycobacterium tuberculosis by ethambutol and dimethyl sulphoxide. J Antimicrob Chemother. Mar. 1995; 35(3):381-90.
Jimenez RA, Willkens RF. Dimethyl Sulphoxide: a perspective of its use in rheumatic diseases. J Lab Clin Med 1982; 100(4):489-500.
John, H., Laudahn, G. Clinical Experiences with the Topical Application of DMSO in Orthopedic Diseases: Evaluation of 4,180 Cases, Annals New York Academy of Sciences, 1967; vol. 141:506-516.
Karlson AG, Ulrich JA, Stock solutions of rifampin remain stable in dimethylsulfoxide for at least 8 months, Appl Microbiol. Oct. 1969; 18(4):692-3.
Khazina et al., Tuberculostatic effect of the combined use of isoniazid and streptomycin with 5-fluorouracil in vitro, Problemy Tuberkuleza, Medicina, Moscow, Russia, vol. 58 (1): 63-66 (1980).
Kim et al. Efficacy of Methylsulfonylmethane (MSM) in Osteoarthritis Pain of The Knee: A Pilot Clinical Trial. Osteoarthritis and Cartilage (2006) 14:286-294.
Knowles R. Clinical Experience with DMSO in Small Animal Practice, Annals New York Academy Sciences (1967) 141:478-483.
Kocsis, et al., “Biological Effects of The Metabolites of Dimethyl Sulfoxide”, Ann N.Y. Acad. Sci. 243, 104 09 (1975).
Koenen NJ, Haag RF, BiaP, RoseP. Perkutane therapie bei aktivierter Gonarthrose. Munch Med Wochenschr 1996; 138 (31-32):534-538.
Kubota et al. Beneficial effect of L-Arginine for Stroke-like episode in MELAS Brain and Development, Amsterdam, JL, vol. 26, No. 7, Oct. 1, 2004; pp. 481-483.
Layman, et al.: “The Absorption, Metabolism and Excretion of Dimethyl Sulfoxide by Rhesus Monkeys,” Life Sciences, vol. 37, pp. 2431-2437, 1985.
Lee, et al.: “Evaluation of Genotoxicity on Plant-Derived Dietary Sulfar,” J. Microbiol. Biotechnol. (2006), 16(5), 817-820.
Life Extension Magazine, Sep. 1999 “The Multi-Purpose Compound MSM”.
Liubinets VI, Kruk MV. Dimexide in the treatment of endobronchitis in patients with destructive forms of pulmonary tuberculosis, Zh Ushn Nos Gorl Bolezn. Nov.-Dec. 1969; 29(6):68-71.
Lockie and Norcross. A Clinical Study on the Effects of Dimethyl Sulfoxide in 103 Patients with Acute and Chronic Musculoskeletal Injuries and Inflammations, Annals New York Academy Sciences (1967) 141:599-602.
Lu, et al.: “A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from Humans,” Journal of Virology, Jul. 1999, p. 5903-5911.
Magnuson, et al.: “Oral developmental toxicity study of methylsulfonylmethane in rats,” Food and Chemical Toxicology 45 (2007) 977-984.
Magnuson, et al.: “Pharmacokinetics and Distribution of [35S]Methylsulfonylmethane following Oral Administration to Rats,” J. Agric. Food Chem. 2007, 55, 1033-1038.
Martin D. and Hauthal H., Dimethyl Sulfoxide—Chapter 12. New York: John Wiley & Sons, 1971.
Matsumoto, J. Clincal Trials of Dimethyl Sulfoxide in Rheumatoid Arthritis Patients in Japan, Annals New York Academy Sciences. 1967; vol. 141:560-568.
Methylsulfonylmethane—Wikipedia, the free encyclopedia. Download from http://en.wikipedia.org/wiki/Methylsulfonylmethane, on Jul. 5, 2010. pp. 1-5.
Mitinskaia LA, Iukhimenko NV, Kamaeva VF. BCG vaccination and increasing the effectiveness of treatment of post-vaccination complications by the use of rifampicin and dimexide. Probl Tuberk. 1994; (5):4-7.
Mohamaddi F, O'Mara K, Unusual Patient Odor Interfering with Care, Resurrection Medical Center, Chicago, Ill. (1996).
MSM—MethylsulfonylMethane. Downloaded from http://pages.prodigy.net/naturedoctor/msm.html on Jul. 5, 2010. pp. 1-6.
Muller U, Urbanczik R. Influence of dimethyl sulfoxide (DMSO) on restoring sensitivity of mycobacterial strains resistant to chemotherapeutic compounds, J Antimicrob Chemother. May 1979; 5(3):326-7.
Murav'ev IuV, Venikova MS, Peskovskaia GN, Riazantseva TA, Sigldin IaA. Effect of dimethylsulphoxide and dimethyl sulfone. Patol Fiziol Eksp Ter Mar.-Apr. 1991; (2):37-39.
Nash DR, Steingrube VA. In vitro drug sensitivity of M. avium-intracellulare complex in the presence and absence of dimethyl sulfoxide. Microbios. 1982; 35(140):71-8.
Oshima Y, Theodosakis J, Amiel D. The Effect of Distilled Methylsulfonylmethane (MSM) on Human Chondrocytes in vitro. World Congress on Osteoarthritis, Ft. Lauderdale, Florida; Osteoarthritis and Cartilage 2007; vol. 15 Supplemental C123:213.
Ostojic et. al. Laboratory Testing of Cabin Air Filters for the Removal of Reduced-Sulfur Odors. New Engine Design and Automotive Filtration SAE Special Publications 1998; 1362:41-58.
Paul M. Interval Therapy with Dimethyl Sulfoxide. Ann NY Acad Sci Mar. 1967; 1(141):586-598.
Paulus E. FDA advisory committee meeting: methotrexate; guidelines for the clinical evaluation of anti-inflammatory drugs; DMSO in scleroderma. Arthritis & Rehumatism Oct. 1986; 10(29):1289-1290.
Pennsaid Monograph, Nuvo Research, 2010.
Penrod, D., Bacharach, B., Templeton, J. Dimethyl Sulfoxide for Incisional Pain after Thoracotomy: Preliminary Report. Annals New York Academy Sciences Mar. 15, 1967; vol. 141(1):493-495.
Potzz GE, Rampey JH, Bejamin F. The effect of dimethyl sulfoxide (DMSO) on antibiotic sensitivity of a group of medically important microorganisms: preliminary report. Ann NY Acad Sci. Mar. 15, 1967; 141(1):261-72.
Pratt, et al.: “A Study of the Absorption of OptiMSM (Methylsulfonylmethane) in Horses,” Proceedings of the 17th Equine Nutrition and Physiology Society, 2001.
Ramirez, et al., DMSO in the Treatment of Mental Patients, Annals of the NY Acad. of Sci., vol. 141: 655-667 (1967).
Rao et al., In vitro induction of nitric oxide by fructose-1,6-diphosphate in the cardiovascular system of rats, Mol. Cell. Biochem. vol. 185:171-175 (1998).
Robertson et al. “L-Arginine reduces neuronal damage after traumatic brain injury in the mouse” Journal of Neurotrauma, vol. 17, No. 10, Oct. 2000, p. 945.
Ropek M, Pawlowska I, Szydlowska T. Effects of dimethyl sulfoxide on tubercle bacilli resistant to INH. Gruzlica. Aug. 1971; 39(8):738-41.
Rosenbaum WM, Rosenbaum EE, Jacob S. The use of dimethyl sulfoxide (DMSO) for the treatment of intractable pain in surgical patients. Surgery 1965: 58.
Roth SH, Shainouse JZ, Efficacy of Safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, controlled clinical trial. Arch Intern Med. Oct. 11, 2004;164(18):2017-23.
Scrubs, online encyclopedia article, accessed Mar. 10, 2010. http://en.wikipedia.org/wiki/Scrubs—(clothing).
Seibert F, Farrelly F, Shepherd C. DMSO and other combatants against bacteria isolated from leukemia and cancer patients. Ann NY Acad Sci Mar. 1967; 1(141):175-201.
Shainhouse JZ, Grierson L, Naseer Z, A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee, American Journal of Therapeutics 0(0) 2010.
Shaklee Health Network, “Methyl Sulfonyl Methane,” [online], 2006 [retrieved on Dec. 16, 2010]. Retrieved from the internet: <URL:http://content.hbiondemand.com/shap/monoVMN.asp?objID=100028]: p. 1-4, especially p. 1, para 1 to p. 2, para 1.
Shanmugam, et al.: “The Effect of Methylsulfonylmethane on Hair Growth Promotion of Magnesium Ascorbyl Phosphate for the Treatment of Alopecia,” Biomolecules & Therapeutics, 17(3), 241-248 (2009). ISSN 1976-9148.
Simon L, et. al. Efficacy and Safety of Topical Diclofenac containing Dimethyl Sulfoxide (DMSO) compared with those of Topical Placebo, DMSO Vehicle and Oral Diclofenac for Knee Osteoarthritis. Pain, 143(2009):238-245.
Smith G, Bertone AL, Kaeding C, et al. Anti-Inflammatory effects of topically applied dimethyl sulphoxide gel on endotoxin-induced synovitis in horses. Am J Vet Res Sep. 1998; 59(9):1149-52.
Steinberg, A. The employment of DMSO as an anti-inflammatory agent and steroid transporter in diversified clinical diseases. Ann NY Acad Sci 1967, 141(1):532-550.
Stürenburg, Enno: “Rapid detection of methicillin-resistant Staphylococcus aureus directly from clinical samples: methods, effectiveness and cost considerations,” GMS German Medical Science 2009, vol. 7, ISSN 1612-3174. pp. 1-19.
Sulfur—MSM—methyl sulfonyl methane—Natural Health Site. A Basic Essential Nutrient Needed Now, More than Ever Before. Downloaded from http://www.all-natural.com/msm.html on Aug. 11, 2010. pp. 1-7.
Szmant, Harry H., “Physical Properties of Dimethyl Sulfoxide and Its Function in Biological Systems,” Annals New York Academy of Sciences, pp. 20-23, Jan. 1975.
Szydlowska T. In Vitro and In Vivo Studies on the role of Dimethylsulfoxide (DMSO) in Resensibilization of Bacterial Strains Resistant to Antibiotics and Chemotherapeutic Agents. Zbl. Bakt. Hyg., I. Abt. Orig. A 239, 270-274 (1977).
Szydlowska T, Pawlowska I. Comparative Studies on the Influence of Dimethylsulfoxide (DMSO) on Reversion to Sensitivity to Isonicotinic Acid Hydrazide (INH) and Rifampicin (RMP) in Resistant Strains of Tubercle Bacilli. Arch Immunol Ther Exp (Warsz). 1976; 24(4):575-77.
Szydlowska T, Pawlowska I. In vivo studies on reversion to sensitivity of INH-resistant tubercle bacilli under the influence of dimethylsulfoxide (DMSO). Arch Immunol Ther Exp (Warsz). 1974; 22(4):559-61.
Szydlowska T. Studies on the role of dimethylsulfoxide in resensibilization of antibiotic-resistant bacterial strains. Arch Immunol Ther Exp (Warsz). 1972; 20(2):193-202.
Szydlowska T. Studies on the role of dimethylsulfoxide in resensibilization of bacterial strains resistant to sulfonamides. Arch Immunol Ther Exp (Warsz). 1972; 20(2):203-207.
Teigland MB, Saurino V. Clinical Evaluation of Dimethyl Sulfoxide in Equine Applications. Ann NY Acad Sci Mar. 1967; 141(1):471-7.
Tiews, et al.: “Metabolism and Excretion of Dimethyl Sulfoxide in Cows and Calves After Topical and Parenteral Application,” Annals New York Academy of Sciences, pp. 139-150. Jan. 1975.
Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized, controlled trial. J Rheumatol. Oct. 2004; 31(10):1893-5.
Usha PR, Naidu MUR. Randomized, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004; 24(6):353-63.
Vignes, Robert P., Ph.D: “Dimethyl Sulfoxide (DMSO): A Superior Solvent,” Semiconductor Safety Association, Annual Meeting Apr. 25-28, 2000, Arlington, VA. pp. 1-47.
Vuopala U, et. al. The Analgesic action of DMSO ointment in arthrosis. Acta Rheum Scand 1971; 17(1):57-60.
Wierzbicki, Homocysteine and cardiovascular disease: a review of the evidence; Diabetes and Vascular Disease Research; Jun. 2007; pp. 143-149; vol. 4, Iss 2; The British Library.
Wiesinger, Arginine metabolism and the synthesis of nitric oxide in the nervous system, Progress in Neurobiology 64, 365-91, 2001.
Williams, et al.: “Metabolism of Dimethyl Sulfide, Dimethyl Sulfoxide, and Dimethyl Sulfone in the Rabbit,” Archives of Biochemistry and Biophysics 117, 84-87 (1966).
Windrum, et al.: “Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres,” Bone Marrow Transplantation (2005) 36, 601-603.
Wong, et al.: “Absorption, Excretion, and Biotransformation of Dimethyl Sulfoxide in Man and Minature Pigs After Topical Applicaton as an 80% Gel,” The Journal of Investigative Dermatology, vol. 56, No. 1, 1971.
Wood, DC, Wood, J. Pharmacologic and Biochemical Considerations of Dimethyl Sulfoxide. Ann NY Acad Sci Jan. 1975; 243:7-19.
Yang, TR, Gas Separation by Adsorption Process, Imperial College Press, 1987 pp. 11-12.
Zhang, et al.: “Assessment of methysulfonylmethane as a permeability enhancer for regional EDTA chelation therapy,” infoma healthcare, Drug Delivery, 2009, 16(5): 243-248.
Zuckner, J. Uddin, J., Gantner, G. Local Application of Dimethyl Sulfoxide and DMSO Combined with Triamcinolone Acetonide in Rheumatoid Arthritis. Ann NY Acad. Sci. Mar. 1967; 1(141):555-9.
Ruslami et al., Pharmacokinetics and Tolerability of a Higher Rifampin Dose Versus the Standard Dose in Pulmonary Tuberculosis Patients, Antimicrobial Agents and Chemotherapy, vol. 51(7):2546-2551 (2007).
Related Publications (1)
Number Date Country
20140058337 A1 Feb 2014 US
Provisional Applications (2)
Number Date Country
60716265 Sep 2005 US
60716368 Sep 2005 US
Continuations (1)
Number Date Country
Parent 12066480 US
Child 13887206 US